Join
Live feed
·
PRReleasevia Quantisnow
Taysha Gene Therapies Inc. logo

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis

ByQuantisnow·Wall Street's wire, on your screen.
TSHA· Taysha Gene Therapies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TSHA (Taysha Gene Therapies Inc.) and more on Quantisnow.